- Home
- ACRS vs HQL Comparison
ACRS vs HQL Comparison
Compare ACRS & HQL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACRS | HQL |
|---|---|---|
| Founded | 2012 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 529.9M | 539.1M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | ACRS | HQL |
|---|---|---|
| Price | $3.89 | $17.89 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $10.36 | N/A |
| AVG Volume (30 Days) | ★ 3.1M | 108.3K |
| Earning Date | 11-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.56% |
| EPS Growth | ★ 69.01 | N/A |
| EPS | N/A | ★ 0.79 |
| Revenue | ★ $1,683,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $23.24 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.10 | $15.66 |
| 52 Week High | $6.60 | $22.67 |
Technical Indicators
Market Signals| Indicator | ACRS | HQL |
|---|---|---|
| Relative Strength Index (RSI) | 46.40 | 47.46 |
| Support Level | $3.18 | $16.78 |
| Resistance Level | $4.67 | $18.22 |
| Average True Range (ATR) | 0.28 | 0.54 |
| MACD | 0.07 | 0.07 |
| Stochastic Oscillator | 72.03 | 39.28 |
Price Performance
Historical ComparisonAbout ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
About HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.